---
title: "SEA STAR released its performance for the first three quarters, with a net profit attributable to the parent company of 30.3088 million yuan, an increase of 12.37%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262051725.md"
description: "SEA STAR released its third-quarter report for 2025, with operating revenue of 485 million yuan in the first three quarters, a year-on-year increase of 7.26%; net profit attributable to the parent company was 30.3088 million yuan, a year-on-year increase of 12.37%; net profit excluding non-recurring gains and losses was 25.6333 million yuan, a year-on-year increase of 46.07%; basic earnings per share were 0.0525 yuan"
datetime: "2025-10-21T12:10:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262051725.md)
  - [en](https://longbridge.com/en/news/262051725.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262051725.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/262051725.md) | [English](https://longbridge.com/en/news/262051725.md)


# SEA STAR released its performance for the first three quarters, with a net profit attributable to the parent company of 30.3088 million yuan, an increase of 12.37%

According to the Zhitong Finance APP, SEA STAR (002137.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 485 million yuan, a year-on-year increase of 7.26%. The net profit attributable to shareholders of the listed company was 30.3088 million yuan, a year-on-year increase of 12.37%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 25.6333 million yuan, a year-on-year increase of 46.07%. The basic earnings per share were 0.0525 yuan

### 相關股票

- [SEA STAR (002137.CN)](https://longbridge.com/zh-HK/quote/002137.CN.md)

## 相關資訊與研究

- [Taiwan February exports +20.6% y/y, below forecasts](https://longbridge.com/zh-HK/news/278353139.md)
- [Kansas City International Airport reopens after brief closure due to unspecified threat](https://longbridge.com/zh-HK/news/278278269.md)
- [Energy price surge a risk to Hungary's rating, S&P says](https://longbridge.com/zh-HK/news/278734499.md)
- [Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China](https://longbridge.com/zh-HK/news/278445287.md)
- [Kainova reports positive top line results from Phase I EPRAD trial](https://longbridge.com/zh-HK/news/278702903.md)